1xbet모바일

• Approximately 1 million people are estimated to suffer from depression in Japan, and about one-third of patients who take treatments such as serotonergic or noradrenergic antidepressants still have unresolved depression symptoms. In countries such as 1xbet모바일 U.S., ABILIFY^®(arpiprazole) has become an important choice as adjunctive 1xbet모바일rapy for 1xbet모바일 treatment of depression, because it may adjust 1xbet모바일 imbalance of dopamine, which is one of 1xbet모바일 chemicals thought to play a role in causing depression.
• ABILIFY was launched in 1xbet모바일 U.S. in 2002 as 1xbet모바일 world's first dopamine D2 receptor partial agonist, and it has become a global product sold in over 60 countries and regions. Otsuka Pharmaceutical has worked tirelessly to innovate new categories by obtaining multiple indications for ABILIFY, an antipsychotic drug with unique mechanism of action and superior safety profile.
• ABILIFY was discovered and developed by Otsuka Pharmaceutical, and this one single antipsychotic drug now owns 13 indications around 1xbet모바일 world, an unprecedented number. ABILIFY for depression/depressive state is 1xbet모바일 third indication approved in Japan. In May 2013, ABILIFY was awarded 1xbet모바일 Japanese Imperial Invention Prize, a national prize awarded to outstanding inventions created through strenuous efforts.

(Tokyo, Japan, June 14, 2013) - Otsuka Pharmaceutical Co., Ltd. today obtained regulatory approval from 1xbet모바일 Japanese Ministry of Health, Labor and Welfare (MHLW) for ABILIFY as 1xbet모바일 first antsipsychotic drug in Japan to treat depression/depressive state as an adjunct 1xbet모바일rapy in patients who showed an inadequate response to existing antidepressant 1xbet모바일rapy.

1 in 15 Japanese people are said to experience depression (major depressive disorder) during 1xbet모바일ir lifetime. 1xbet모바일re are approximately 1 million Japanese people with depression, and 1xbet모바일 number of diagnosed patients has increased 2.4-fold over 1xbet모바일 last twelve years. Research shows that men are more prone to depression by 1xbet모바일 time 1xbet모바일y reach 1xbet모바일ir forties, in 1xbet모바일 prime of 1xbet모바일ir careers, and women are more to depression after reaching age thirty or older. 1xbet모바일re are more women depressed than men across all age categories. Only 30% to 40% patients who take antidepressants get full relief from depression symptoms, and 1xbet모바일refore different choices of 1xbet모바일rapies are much needed to satisfy those with unresolved conditions.

Otsuka Pharmaceutical conducted a Phase-III clinical trial as support for this regulatory approval for ABILIFY as adjunctive 1xbet모바일rapy for depression. 1xbet모바일 primary efficacy endpoint for 1xbet모바일 trial was 1xbet모바일 mean change, from baseline to 1xbet모바일 completion of this randomized, double-blinded treatment phase, in a standard measure called MADRS (Montgomery-Asberg Depression Rating Scale) of patients diagnosed with depression. Patients taking ABILIFY showed significant improvements in terms of MADRS total score reduction, compared to those taking placebo. 1xbet모바일 most frequently observed adverse reactions were akathisia, tremor, constipation, and adipsia. In a long-term, 52-week clinical trial extending from this Phase-III clinical trial, 1xbet모바일 average MADRS score remained stable and with no safety issues.

In Japan, ABILIFY was approved as an antipsychotic for 1xbet모바일 treatment of schizophrenia in 2006, followed by approval of an additional indication for 1xbet모바일 improvement of manic episodes associated with bipolar disorder in 2012. ABILIFY for depression/depressive state is 1xbet모바일 third indication approved in Japan

In May 2013, ABILIFY was awarded 1xbet모바일 Japanese Imperial Invention Prize, a national prize awarded to outstanding inventions created through strenuous efforts. Otsuka's team of researchers who created aripiprazole was honored for discovering an effective treatment for schizophrenia with fewer side effects than conventional treatments.

Recipients of 1xbet모바일 Awards:
Imperial 1xbet모바일vention Prize - Yasuo Oshiro, Seiji Sato, Nobuyuki Kurahashi
Distinguishing Service Prize for Employment 1xbet모바일 Invention - Taro Iwamoto (President and Representative Director 1xbet모바일 Otsuka Pharmaceutical Co., Ltd.)

Otsuka Pharmaceutical will continue its passionate, longstanding commitment to CNS drug research and development to address unmet medical needs 1xbet모바일 patients with mental disorders.